| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DRB5 |
| Uniprot No | Q30154 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-266aa |
| 氨基酸序列 | MVCLKLPGGSYMAKLTVTLMVLSSPLALAGDTRPRFLQQDKYECHFFNGTERVRFLHRDIYNQEEDLRFDSDVGEYRAVTELGRPDAEYWNSQKDFLEDRRAAVDTYCRHNYGVGESFTVQRRVEPKVTVYPARTQTLQHHNLLVCSVNGFYPGSIEVRWFRNSQEEKAGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRAQSESAQSKMLSGVGGFVLGLLFLGAGLFIYFKNQKGHSGLHPTGLVS |
| 预测分子量 | 30,0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DRB5重组蛋白的3篇参考文献示例：
---
1. **标题**: "Structural characterization of HLA-DRB5*01:01 and its interaction with myelin-derived peptides in multiple sclerosis"
**作者**: Yamaguchi, H. et al.
**摘要**: 本研究通过X射线晶体学解析了重组HLA-DRB5蛋白与髓鞘碱性蛋白多肽复合物的三维结构，揭示了DRB5抗原结合槽的关键氨基酸残基如何影响多肽结合特异性，为多发性硬化症的自身免疫机制提供结构依据。
2. **标题**: "Efficient prokaryotic expression and purification of functional HLA-DRB5 for antigen presentation assays"
**作者**: Smith, J.E. & Chen, L.
**摘要**: 报道了一种利用大肠杆菌系统高效表达可溶性HLA-DRB5重组蛋白的方法，并通过体外T细胞活化实验验证其功能。该技术为研究DRB5限制性抗原的免疫应答提供了可靠工具。
3. **标题**: "Allelic variation in HLA-DRB5 modulates CD4+ T cell responses in rheumatoid arthritis"
**作者**: Müller, R. et al.
**摘要**: 通过重组DRB5蛋白与不同基因变体的功能对比，发现特定单倍型(如DRB5*02:01)显著增强对瓜氨酸化肽段的呈递能力，进而促进类风湿关节炎患者中促炎性T细胞的活化。
---
注：上述文献为示例性内容，实际引用时建议通过PubMed或Web of Science核实具体研究。
DRB5 is a member of the MHC class II β-chain family, encoded by the HLA-DRB5 gene within the human leukocyte antigen (HLA) complex on chromosome 6. It plays a critical role in antigen presentation by forming heterodimers with the MHC class II α-chain (DRA), creating functional HLA-DR molecules expressed on antigen-presenting cells. These molecules bind exogenous peptide antigens and present them to CD4+ T cells, initiating adaptive immune responses. DRB5 is notably associated with the HLA-DR2 haplotype (HLA-DRB1*15:01 and HLA-DRB5*01:01), which has been linked to autoimmune diseases like multiple sclerosis (MS) and susceptibility to certain infections.
Recombinant DRB5 protein refers to the engineered form of this β-chain, produced using expression systems like *E. coli* or mammalian cell lines. It is commonly generated as a soluble, purified protein for research purposes, often co-expressed with DRA to mimic native HLA-DR5 complexes. The recombinant protein retains the peptide-binding groove structure, enabling studies on antigen interaction, T cell receptor (TCR) recognition, and autoimmune epitope mapping. Its production facilitates investigations into HLA-disease associations, particularly in MS, where DRB5-derived peptides may contribute to pathogenic T cell activation.
Researchers utilize DRB5 recombinant proteins to explore mechanisms of immune dysregulation, develop antigen-specific therapies, or screen small-molecule inhibitors targeting pathogenic HLA-peptide-TCR interactions. Structural studies using X-ray crystallography or cryo-EM often employ recombinant DRB5 to elucidate molecular details of antigen presentation. Additionally, it serves as a tool for diagnostic assays detecting autoantibodies or autoreactive T cells in autoimmune conditions. Despite its functional overlap with other HLA-DR β-chains, DRB5's unique genetic linkage and disease associations make it a distinct focus for understanding HLA-mediated immunity and pathology.
×
